Global Endocrinology Drugs Market Size study & Forecast, by Therapy Area (Diabetes drugs, HGH, Thyroid hormone disorders, Others), by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), and Regional Analysis, 2023-2030

Global Endocrinology Drugs Market Size study & Forecast, by Therapy Area (Diabetes drugs, HGH, Thyroid hormone disorders, Others), by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), and Regional Analysis, 2023-2030

Global Endocrinology Drugs Market is valued at approximately USD 25084.24 million in 2022 and is anticipated to grow with a healthy growth rate of more than 7.82% over the forecast period 2023-2030. Endocrinology drugs deals with endocrine disorders, which are related to hormone imbalance and dysfunction in the endocrine system. Endocrinology drugs play an important role in providing therapeutic options for patients suffering from the endocrine disorder. The endocrinology drug market is being driven by factors such as Growing clinical trials of endocrinology drugs and rising endocrine disorders such as diabetes and thyroid.

Endocrinology drugs used to treat diabetes include insulin, which is a hormone that helps regulate blood sugar levels, and oral hypoglycemic agents (OHAs) such as metformin, sulfonylureas, and meglitinides. These drugs are designed to lower blood sugar levels and prevent complications associated with diabetes. According to the World health organization 537 million people lining with diabetes in 2021 and projections show this number is rising to 783 million people diabetic by 2045. Thus, rising in endocrine disorders fuels the market growth. In addition, advanced drug development and a growing aging population are creating a lucrative opportunity for market growth. However, Patent expiry on major endocrinology drugs is the major challenge impeding the endocrinology drugs market growth during the forecast years 2023-2030.

The key regions considered for the Global Endocrinology Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 due to high healthcare expenses and a high level of awareness in public, USA spends around 17.8% of the total GDP on healthcare. Where Asia Pacific is expected to have significant growth owing to factors such as rising disease prevalence, rising healthcare expenditure, a rapidly growing population and Government initiatives.

Major market player included in this report are:
Abbott Laboratories
Acerus Pharmaceuticals Corp.
Hanmi Pharm Co. Ltd.
Oramed Pharmaceuticals Inc.
Pfizer Inc.
F. Hoffmann La Roche Ltd.
GlaxoSmithKline Plc
Biocon Ltd.
Ascendis Pharma AS
Endo International Plc

Recent Developments in the Market:
On February 2022, Biocon announced the acquisition of Viatris’ biosimilar portfolio for USD 3.335 billion. This acquisition strengthened Biocon’s biosimilar product portfolio and improved its revenue generation.

In Aug 2021, The U.S. Food and Drug Administration (FDA) approved an expanded label for Eli Lilly and Company's rapid-acting Endocrinology Drugs, Lyumjev® (Endocrinology Drugs lispro-AABC injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous Endocrinology Drugs infusion (CSII) with an Endocrinology Drugs pump.

In July 2021, Semglee, a first-of-its-kind Endocrinology Drugs product made by India’s Biocon, gets United States approval. Semglee, manufactured by Biocon Biologics, a Bengaluru-based pharmaceutical company, is both interchangeable with and biosimilar to Lantus, a long-acting Endocrinology Drugs product already approved in the United States.

Global Endocrinology Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Therapy Area, Distribution Channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy Area:
Diabetes drugs
HGH
Thyroid hormone disorders
Others

By Distribution Channel:
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Abbott Laboratories
Acerus Pharmaceuticals Corp.
Hanmi Pharm Co. Ltd.
Oramed Pharmaceuticals Inc.
Pfizer Inc.
F. Hoffmann La Roche Ltd.
GlaxoSmithKline Plc
Biocon Ltd.
Ascendis Pharma AS
Endo International Plc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.